710193Peptinnovate's re-evolution in treating inflammatory diseases:Peptinnovate Limited will build on nature's ingenuity by exploiting naturally occurring molecules, which are present in ~2 billion people worldwide efficacious in treating inflammatory diseaseClosedGRD Proof of ConceptInnovate UKTuberculosis (TB) bacteria are present in about 2 billion people worldwide; they have evolved over 1000’s of years to remain hidden in the body by producing proteins that modulate the host's immune system. These chaperonin proteins have been shown to interact with and reduce the body's natural inflammatory process. Peptinnovate’s innovation: Peptinnovate’s innovative approach is to unlock the anti-inflammatory activity of these proteins and to develop new medicines for debilitating diseases such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD) by building on evolution and nature's ingenuity to modify these proteins to more drug-like molecules. Aim: This project will enable our lead molecule PIN201104 to be progressed through the preclinical activities to deliver a molecule towards Phase 1 and 2 clinical trials in rheumatoid arthritis. Objectives: ? To further expand the demonstrated efficacy in key animal models of inflammation ? To demonstrate the safety in toxicology and safety studies ? To demonstrate manufacturability to the desired quality standard ? To prepare a suitable stable formulation for future dosing in the clinic Main benefits, likely outcomes and impacts: The worldwide market for inflammatory disease treatment is vast (>$70 billion), however recent safety scares have been attributed to a number of key drugs. A novel anti-inflammatory medicine with a benign safety profile is desperately required by millions of patients. Peptinnovate’s approach of building on nature’s ingenuity and design means that the safety profile and efficacy represent a high probability of success. This paradigm shift in potential treatment options will have a profound impact on the lives of millions of patients, reducing the burden on the healthcare providers and helping to build a large, UK based, sustainable biopharmaceutical company.